ScinoPharm Taiwan Statistics

Total Valuation

ScinoPharm Taiwan has a market cap or net worth of TWD 17.59 billion. The enterprise value is 14.29 billion.

Market Cap	17.59B
Enterprise Value	14.29B

Important Dates

The next estimated earnings date is Thursday, February 27, 2025.

Earnings Date	Feb 27, 2025
Ex-Dividend Date	Jul 4, 2024

Share Statistics

ScinoPharm Taiwan has 790.74 million shares outstanding. The number of shares has increased by 0.07% in one year.

Current Share Class	n/a
Shares Outstanding	790.74M
Shares Change (YoY)	+0.07%
Shares Change (QoQ)	+0.03%
Owned by Insiders (%)	0.01%
Owned by Institutions (%)	3.63%
Float	247.21M

Valuation Ratios

The trailing PE ratio is 44.05 and the forward PE ratio is 59.33.

PE Ratio	44.05
Forward PE	59.33
PS Ratio	5.04
PB Ratio	1.69
P/TBV Ratio	1.69
P/FCF Ratio	68.40
P/OCF Ratio	n/a
PEG Ratio	n/a

Financial Ratio History

Enterprise Valuation

The stock's EV/EBITDA ratio is 15.40, with an EV/FCF ratio of 55.57.

EV / Earnings	35.79
EV / Sales	4.09
EV / EBITDA	15.40
EV / EBIT	32.02
EV / FCF	55.57

Financial Position

The company has a current ratio of 9.35, with a Debt / Equity ratio of 0.06.

Current Ratio	9.35
Quick Ratio	6.41
Debt / Equity	0.06
Debt / EBITDA	0.73
Debt / FCF	2.63
Interest Coverage	55.16

Financial Efficiency

Return on equity (ROE) is 3.86% and return on invested capital (ROIC) is 2.54%.

Return on Equity (ROE)	3.86%
Return on Assets (ROA)	2.39%
Return on Capital (ROIC)	2.54%
Revenue Per Employee	6.47M
Profits Per Employee	739,604
Employee Count	540
Asset Turnover	0.30
Inventory Turnover	1.20

Taxes

Income Tax	n/a
Effective Tax Rate	n/a

Stock Price Statistics

The stock price has decreased by -12.23% in the last 52 weeks. The beta is 0.39, so ScinoPharm Taiwan's price volatility has been lower than the market average.

Beta (5Y)	0.39
52-Week Price Change	-12.23%
50-Day Moving Average	22.72
200-Day Moving Average	25.60
Relative Strength Index (RSI)	49.23
Average Volume (20 Days)	377,071

Short Selling Information

Short Interest	n/a
Short Previous Month	n/a
Short % of Shares Out	n/a
Short % of Float	n/a
Short Ratio (days to cover)	n/a

Income Statement

In the last 12 months, ScinoPharm Taiwan had revenue of TWD 3.49 billion and earned 399.39 million in profits. Earnings per share was 0.51.

Revenue	3.49B
Gross Profit	1.38B
Operating Income	446.42M
Pretax Income	490.18M
Net Income	399.39M
EBITDA	911.56M
EBIT	446.42M
Earnings Per Share (EPS)	0.51

Full Income Statement

Balance Sheet

The company has 3.98 billion in cash and 676.13 million in debt, giving a net cash position of 3.30 billion or 4.17 per share.

Cash & Cash Equivalents	3.98B
Total Debt	676.13M
Net Cash	3.30B
Net Cash Per Share	4.17
Equity (Book Value)	10.44B
Book Value Per Share	13.20
Working Capital	5.79B

Full Balance Sheet

Cash Flow

In the last 12 months, operating cash flow was 554.74 million and capital expenditures -297.53 million, giving a free cash flow of 257.21 million.

Operating Cash Flow	554.74M
Capital Expenditures	-297.53M
Free Cash Flow	257.21M
FCF Per Share	0.33

Full Cash Flow Statement

Margins

Gross margin is 39.53%, with operating and profit margins of 12.78% and 11.43%.

Gross Margin	39.53%
Operating Margin	12.78%
Pretax Margin	14.03%
Profit Margin	11.43%
EBITDA Margin	26.10%
EBIT Margin	12.78%
FCF Margin	7.36%

Dividends & Yields

This stock pays an annual dividend of 0.30, which amounts to a dividend yield of 1.34%.

Dividend Per Share	0.30
Dividend Yield	1.34%
Dividend Growth (YoY)	-16.67%
Years of Dividend Growth	n/a
Payout Ratio	59.40%
Buyback Yield	-0.07%
Shareholder Yield	1.27%
Earnings Yield	2.27%
FCF Yield	1.46%

Dividend Details

Stock Splits

The last stock split was on August 10, 2017. It was a forward split with a ratio of 1.04.

Last Split Date	Aug 10, 2017
Split Type	Forward
Split Ratio	1.04

Scores

ScinoPharm Taiwan has an Altman Z-Score of 10.56.

Altman Z-Score	10.56
Piotroski F-Score	n/a